Eupraxia Pharmaceuticals is trading 6.42% up now at $8.78 after announcing on September 8, 2026, that its shares began trading on the Nasdaq Global Select Market.
- Upcoming investor-conference participation could improve visibility among institutional investors.
- The Nasdaq upgrade is the clearest company-specific catalyst; broader healthcare sentiment is negative, making the strength notably company-driven.
- No new earnings release or regulatory decision was identified for September 9, 2026.